Excretion of potassium ion by prostanoic acid derivatives

Abstract

Amethod for inducing decrease in potassium ion concentration in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in inducing decrease in potassium ion concentration in the blood wherein said concentration is increased or for improving extracorporeal excretion of potassium ion in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in improving extracorporeal excretion of potassium ion concentration is increased.

What we claimed is: 
     
       1. A method for inducing decrease in potassium ion concentration in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, .[.a derivative of a prostanoic acid having the skeleton.]. ##STR5## .Iadd.a 15-keto-16-mono- or di-haloprostaglandin represented by formula (I) .Iaddend.in an amount effective in inducing decrease in potassium ion concentration in the blood .[.wherein said concentration is increased.]..Iadd.: ##STR6##.Iaddend. wherein X and Y are independently selected from the group consisting of hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl and oxo, with the proviso that at least one of X and Y is not hydrogen; the five-membered ring shown in structural formula (I) may contain at least one double bond; Z is hydrogen or halogen; A is --CH 2  OH, --COCH 2  OH, --COOH or a functional derivative thereof; R 1  is a bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl; R 2  is a saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with oxo, hydroxy, halo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy; R 2  contains at least four carbon atoms, with the proviso that the third carbon atom of R 2  removed from the five-membered ring being substituted with an oxo group and the fourth carbon atom of R 2  removed from the five-membered ring being substituted with one or two halogen atoms. 
     
     
       2. The method according to claim 1, for compensating reduced renal function. 
     
     
       3. The method according to claim 1, for treating renal insufficiency. .[.4. The method according to claim 1, wherein the prostanoic acid derivative has one or two halogen atoms at position 16..]. .[.5. The method according to claim 1, wherein the prostanoic acid derivative has an oxo group at 
     
     
        position 15..]. 6. The method according to claim 1, wherein the prostanoic 
     
     
        acid derivative has a saturated bond between positions 13 and 14. 7. The method according to claim 1, wherein the prostanoic acid is a 
     
     
        prostaglandin derivative. 8. The method according to claim 1, wherein the prostanoic acid derivative is a 15-keto-16-mono- or di-fluoroprostaglandin 
     
     
        compound. 9. A method for improving extracorporeal excretion of potassium ion in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, .[.a derivative of a prostanoic acid having the skeleton.]. ##STR7## .Iadd.a 15-keto-16-mono- or di-haloprostaglandin represented by formula (I) .Iaddend.in an amount effective in improving extracorporeal excretion of potassium ion .[.concentration is increased.]..Iadd.: ##STR8##.Iaddend. wherein X and Y are independently selected from group consisting of hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl and oxo, with the proviso that at least one of X and Y is not hydrogen; the five-membered ring shown in structural formula (I) may contain at least one double bond; Z is hydrogen or halogen; A is --CH 2  OH, --COCH 2  OH, --COOH or a functional derivative thereof; R 1  is a bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl; R 2  is a saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with oxo, hydroxy, halo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy; R 2  contains at least four carbon atoms, with the proviso that the third carbon atom of R 2  removed from the five-membered ring being substituted with an oxo group and the fourth carbon atom of R 2  removed from the five-membered ring being substituted with one or two 
     
     
        halogen atoms. 10. The method according to claim 9, wherein the excretion 
     
     
        occurs through the intestine. 11. The method according to claim 9, for 
     
     
        treating hyperkalemia. 12. The method according to claim 9, for 
     
     
        compensating reduced renal function. 13. The method according to claim 9, for treating renal insufficiency. .[.14. The method according to claim 9, wherein the prostanoic acid derivative has one or two halogen atoms at position 16..]. .[.15. The method according to claim 9, wherein the 
     
     
        prostanoic acid derivative has an oxo group at position 15..]. 16. The method according to claim 9, wherein the prostanoic acid derivative has a 
     
     
        saturated bond between positions 13 and 14. 17. The method according to 
     
     
        claim 9, wherein the prostanoic acid is a prostaglandin derivative. 18. The method according to claim 9, wherein the prostanoic acid 
     
     
        derivative is a 15-keto-16-mono- or di-fluoroprostaglandin compound. 19. The method according to claim 7 wherein the derivative of a prostanoic 
     
     
        acid is a PGA, PGB, PGC, PGD, PGE, PGF, PGG, PGH, PGI, or PGJ. 20. The method of claim 17 wherein the derivative of a prostanoic acid is a PGA, PGB, PGC, PGD, PGE, PGF, PGG, PGH, PGI or PGJ.